Expanded Access Program for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic, for the Treatment of Serious Infections Caused by Staphylococcus Aureus.
Latest Information Update: 31 May 2019
At a glance
- Drugs AP SA01 (Primary)
- Indications Staphylococcal infections
- Focus Expanded access; Therapeutic Use
- Sponsors AmpliPhi Biosciences Corporation; Armata Pharmaceuticals
- 24 May 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Mar 2019 Results presented in the AmpliPhi Biosciences Corporation media release.
- 08 Oct 2018 According to an AmpliPhi Biosciences media release, the treatment was conducted under emergency protocols per the Australian Therapeutic Goods Administration's (TGA) Special Access Scheme (SAS).